Format

Send to

Choose Destination
J Am Acad Psychiatry Law. 2017 Dec;45(4):472-477.

Prescribing Opioid Replacement Therapy in U.S. Correctional Settings.

Author information

1
Drs. Farahmand and Modesto-Lowe are Principal Psychiatrists, Connecticut Valley Hospital, Middletown, CT. Drs. Farahmand and Chaplin are Staff Psychiatrists, Community Mental Health Affiliates, New Britain, CT. paf9069@nyp.org.
2
Drs. Farahmand and Modesto-Lowe are Principal Psychiatrists, Connecticut Valley Hospital, Middletown, CT. Drs. Farahmand and Chaplin are Staff Psychiatrists, Community Mental Health Affiliates, New Britain, CT.

Abstract

Opioid addiction is a chronic, relapsing disorder associated with criminality, unemployment, infectious diseases, and legal problems. Such addictions are typically over-represented in correctional populations. Inmates with untreated opioid addiction often relapse shortly after release into the community, thereby increasing the risk of overdose, serious illnesses (HIV, hepatitis C) and psychosocial problems (e.g., crimes, recidivism, and reincarceration). There are three U.S. Food and Drug Administration-approved medications for the treatment of opioid use disorder: methadone, buprenorphine, and naltrexone. Opioid replacement therapies (ORTs) are associated with significant benefits, including reducing the incidences of HIV, criminality, and opioid-related mortality. However, most opioid-dependent Americans who are incarcerated are forced to discontinue ORT upon prison entry. This article offers a rationale for providing ORT to addicted prisoners while incarcerated and providing appointments with outpatient providers for continued treatment.

PMID:
29282239

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center